[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,917,066
  • Shares Outstanding, K 100,550
  • Annual Sales, $ 2,861 M
  • Annual Income, $ 478,600 K
  • EBIT $ 789 M
  • EBITDA $ 806 M
  • 60-Month Beta 0.34
  • Price/Sales 5.50
  • Price/Cash Flow 31.20
  • Price/Book 4.61

Options Overview Details

View History
  • Implied Volatility 35.74% (+0.44%)
  • Historical Volatility 32.68%
  • IV Percentile 52%
  • IV Rank 46.26%
  • IV High 51.29% on 04/16/26
  • IV Low 22.35% on 08/29/25
  • Expected Move (DTE 18) 9.44 (5.96%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 44
  • Volume Avg (30-Day) 288
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 11,914
  • Open Int (30-Day) 12,341
  • Expected Range 148.87 to 167.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.78
  • Number of Estimates 7
  • High Estimate $2.17
  • Low Estimate $1.47
  • Prior Year $1.06
  • Growth Rate Est. (year over year) +67.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
129.76 +22.00%
on 04/30/26
162.39 -2.52%
on 05/14/26
+27.07 (+20.63%)
since 04/29/26
3-Month
125.11 +26.53%
on 03/24/26
162.39 -2.52%
on 05/14/26
+26.05 (+19.70%)
since 02/27/26
52-Week
121.42 +30.37%
on 05/30/25
162.39 -2.52%
on 05/14/26
+35.27 (+28.67%)
since 05/28/25

Most Recent Stories

More News
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

SAN DIEGO , May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:

NBIX : 158.30 (+1.22%)
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

SAN DIEGO , May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact...

NBIX : 158.30 (+1.22%)
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

SAN DIEGO , May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's...

NBIX : 158.30 (+1.22%)
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

SAN DIEGO , May 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose...

NBIX : 158.30 (+1.22%)
Neurocrine: Q1 Earnings Snapshot

Neurocrine: Q1 Earnings Snapshot

NBIX : 158.30 (+1.22%)
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year

NBIX : 158.30 (+1.22%)
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

SAN DIEGO , May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20...

NBIX : 158.30 (+1.22%)
Can Neurocrine Biosciences Justify Its Valuation Without Pipeline Surprises?

Barchart Research What to Expect from NBIX Earnings NBIX Generated May 4, 2026 Current Price $134.07 EPS Estimate $$1.28 Consensus Rating Strong Buy Average Move 6.93% Can Neurocrine Biosciences Justify...

NBIX : 158.30 (+1.22%)
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

SAN DIEGO , May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive...

NBIX : 158.30 (+1.22%)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

SAN DIEGO , May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability...

NBIX : 158.30 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 163.43
2nd Resistance Point 161.25
1st Resistance Point 159.78
Last Price 158.30
1st Support Level 156.13
2nd Support Level 153.95
3rd Support Level 152.48

See More

52-Week High 162.39
Last Price 158.30
Fibonacci 61.8% 146.74
Fibonacci 50% 141.91
Fibonacci 38.2% 137.07
52-Week Low 121.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.